AN2 Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $183.16 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
AN2 Therapeutics Inc had its IPO on 2022-03-25 under the ticker symbol ANTX.
The company operates in the Healthcare sector and Biotechnology industry. AN2 Therapeutics Inc has a staff strength of 26 employees.
Shares of AN2 Therapeutics Inc opened at $10.91 at the start of the last trading session i.e. 2023-03-25.
The stocks traded within a range of $10.05 - $11, and closed at $10.38.
This is a -4.24% slip from the previous day's closing price.
A total volume of 20,100 shares were traded at the close of the day’s session.
In the last one week, shares of AN2 Therapeutics Inc have increased by +30.73%.
AN2 Therapeutics Inc's Key Ratios
AN2 Therapeutics Inc has a market cap of $183.16 million, indicating a price to book ratio of 1.8158 and a price to sales ratio of 0.
In the last 12-months AN2 Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures AN2 Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, AN2 Therapeutics Inc’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.
In Q3, AN2 Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
AN2 Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into AN2 Therapeutics Inc’s profitability.
AN2 Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.3379. Its price to sales ratio in the trailing 12-months stood at 0.
AN2 Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $110.01 million
- Total Liabilities
- $4.43 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
AN2 Therapeutics Inc ended 2023 with $110.01 million in total assets and $0 in total liabilities. Its intangible assets were valued at $110.01 million while shareholder equity stood at $105.57 million.
AN2 Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $4.43 million in other current liabilities, in common stock, $-77881000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $28.80 million and cash and short-term investments were $104.38 million. The company’s total short-term debt was $73,000 while long-term debt stood at $0.
AN2 Therapeutics Inc’s total current assets stands at $107.30 million while long-term investments were $1.99 million and short-term investments were $75.58 million. Its net receivables were $0 compared to accounts payable of $1.44 million and inventory worth $0.
In 2023, AN2 Therapeutics Inc's operating cash flow was $-2317000.00 while its capital expenditure stood at $0.
Comparatively, AN2 Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
AN2 Therapeutics Inc stock is currently trading at $10.38 per share. It touched a 52-week high of $23.58 and a 52-week low of $23.58. Analysts tracking the stock have a 12-month average target price of $23.33.
Its 50-day moving average was $11.4 and 200-day moving average was $11.85 The short ratio stood at 7.74 indicating a short percent outstanding of 0%.
Around 3534.7% of the company’s stock are held by insiders while 5048% are held by institutions.
Frequently Asked Questions About AN2 Therapeutics Inc
Similar Industry Stocks (Biotechnology)
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.